BioticsAI CEO Robhy Bustami discussed the challenges of maintaining team motivation while seeking FDA approval for ultrasound and AI healthcare technology today.
The process is critical because the startup's technology aims to save babies and protect mothers, but the timeline for regulatory clearance remains uncertain. For healthcare startups, the gap between product development and market entry can lead to employee burnout and investor hesitation.
Speaking on the Build Mode podcast with host Isabelle Johannessen, Bustami said he described the reality of building in the healthcare sector. He said the company is navigating the long road to FDA approval while trying to keep the team focused on the eventual impact of their technology [1].
Bustami highlighted the financial hurdles associated with early-stage development. He said the initial capital raised by BioticsAI was less than $100,000 [3]. This limited funding required the team to be lean while pursuing complex medical certifications.
The company uses a combination of ultrasound and artificial intelligence to improve maternal and infant health outcomes [1]. Because FDA approval is not guaranteed, the leadership focuses on creating milestones that keep the staff engaged, despite the lack of a commercial product on the market [2].
Bustami said that attracting investors during this phase requires a balance of transparency regarding regulatory risks and a clear vision of the technology's potential. The goal is to ensure the technology eventually reaches the market to provide critical care to mothers and infants [2].
“BioticsAI is using ultrasound and AI to protect mothers and babies.”
The experience of BioticsAI underscores the 'valley of death' facing med-tech startups, where high development costs and rigid regulatory timelines create a precarious environment. By focusing on internal momentum and lean initial funding, the company is attempting to bridge the gap between technical innovation and legal marketability in the U.S. healthcare system.
